TLR4 sits at the front line of the body’s defense against bacteria. When the portion of the receptor exposed outside the cell detects a bacterial molecule, the receptor undergoes changes that prompt two TLR4 proteins to come together as dimers, and those dimers can then trigger cascades inside the cell, including the NF-κB pathway, one of the principal drivers of inflammation. The receptor can also respond to certain non-bacterial molecules associated with tissue damage, which helps explain why its misfiring is tied to such a broad range of inflammatory conditions. Despite decades of interest, no FDA-approved drug specifically blocks TLR4, in part because the receptor’s most druggable-looking surfaces are also the hardest to engage with precision. The Scripps team’s strategy was to aim not at the well-studied extracellular region but at the stretch of the protein buried inside the membrane, a site long considered beyond the reach of rational design.

The biological rationale for this approach emerged from a simple question posed by first author Colleen Maillie, a research project analyst at Scripps Research. Scientists had generally assumed that the regions of TLR4 exposed outside and inside the cell were the main signaling drivers, with the membrane-spanning segment serving a purely structural role. To test that assumption, the researchers introduced a fragment of TLR4, comprising the membrane-spanning region plus a small neighboring section, into human cells grown in the laboratory. The fragments readily associated with full-length TLR4 within the membrane, an interaction the team detected using a screening method recently developed in the Mravic lab that emits light when tagged proteins come into close proximity. Crucially, the presence of these fragments reduced overall NF-κB signaling responses, providing the first concrete evidence that the transmembrane region is not a passive tether but an active determinant of the receptor’s inflammatory output.

That screening assay matters as much as the molecules it helped find. Measuring whether two proteins interact inside a lipid bilayer is far harder than doing so in water, because most conventional biochemical tools are optimized for aqueous environments. The Mravic lab’s light-up approach was built specifically to identify which synthetic proteins target membrane proteins, and the TLR4 fragments provided an early demonstration that the method works in practice. With that tool in hand, the team could move from observation to engineering: if simply presenting the receptor with its own transmembrane sequence could dampen signaling, then a purpose-built synthetic protein designed to bind that region more tightly might dial the response down even further.

Designing such a molecule required confronting a stubborn gap in computational biology. Protein design software has matured enormously for soluble proteins, whose folding rules in water are increasingly well captured by physics-based equations and machine learning models. Membranes are a different story. The cell membrane consists of two compact layers of oily molecules, an environment with biochemical properties radically different from the water-based settings where most proteins reside, and many of the rules governing how proteins fold and function within those greasy layers remain poorly understood. As Mravic explained, models for protein interactions in water have become increasingly accurate, but for membrane proteins they are not, because there are unique atomic details underlying molecular biophysics in lipid bilayers that current equations and AI models do not accurately capture.

Unable to rely on the software’s raw predictions, the team treated the computer-generated three-dimensional blueprints as starting points rather than finished designs. They then applied custom design criteria developed in the Mravic lab to optimize what the researchers call apolar packing, the tightness with which the chemical structures of the designed proteins fit together with their TLR4 target. The underlying theory, which the team encoded into software, holds that maximizing apolar packing produces more stable protein interactions within the hydrophobic membrane environment. From the many structural options generated, the researchers narrowed the field to the nine candidates with the best predicted biophysical and chemical features and took those forward into tests in living cells.

The results validated the strategy with striking efficiency. Using the same light-up screening approach, the team found that eight of the nine synthetic proteins showed signs of associating with TLR4. Three emerged as the strongest candidates, and one, designated Design-6, showed the most robust evidence of interaction along with several other appealing qualities. Unlike the naturally occurring transmembrane fragments tested earlier, Design-6 did not aggregate as much, a critical property for any molecule that might eventually be developed as a biologic. Most importantly, Design-6 substantially reduced NF-κB inflammatory signaling, demonstrating that a rationally designed transmembrane protein could not merely bind to its target but measurably alter the receptor’s biological function.

The implications extend well beyond TLR4 itself. The study establishes that the membrane-embedded regions of immune receptors can be treated as legitimate, programmable drug sites, opening what the researchers describe as a potential launchpad for a new class of biologics that operate from within the membrane. It also delivers a set of computational tools, built around the apolar packing design criteria, that other laboratories can apply to proteins embedded in membranes, a category that includes many of the most sought-after targets in modern pharmacology. Because roughly a quarter of known drug targets are membrane proteins, design methods that work in lipid bilayers rather than despite them could reshape how researchers approach targets that conventional antibodies and small molecules have failed to reach.

Considerable work remains before any of this reaches patients. The experiments were conducted in human embryonic kidney cells, which are convenient for laboratory study but not especially relevant to inflammation-driven disease, so the team must confirm that the approach holds in more disease-relevant cell types such as liver cells and immune cells. Delivery poses another obstacle: these are oily synthetic proteins that must reach and insert into cell membranes, and no established clinical method yet exists for getting them there. Maillie acknowledged the challenge candidly, noting that this is an innovative space that carries a lot of risk and a long roadmap to the clinic, but emphasizing that the team has shown that with clever design and biophysics, they are getting closer. Maillie, Ward and Mravic are inventors on a provisional patent application titled Compositions and Methods for Inhibiting Toll-Like Receptor 4 Mediated Inflammation, signaling that the group intends to pursue the therapeutic potential of the platform.

What makes the study resonate beyond its immediate findings is the way it reframes a familiar target. TLR4 has long been described as a key sensor of bacteria that activates and mobilizes immune cells to fight infection, and, in Ward’s framing, as both a sensor and a dial to tune innate immunity, one that vaccine adjuvants can turn up and inhibitors can turn down. The Scripps work shows that the dial’s most sensitive setting may lie in the part of the receptor nobody thought to touch. By proving that a designed transmembrane protein can find its target, bind it, and quiet the inflammatory signal it produces, the study turns a long-standing blind spot in protein design into a working blueprint, and hands the field both a molecule and a method for building the next ones.

Subject of Research: De novo computational design of transmembrane proteins that inhibit the innate immune receptor TLR4

Article Title: Computer-designed protein targets immune receptor linked to inflammation at a new “undruggable” site

Article References: Computer-designed protein targets immune receptor linked to inflammation at a new “undruggable” site. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: TLR4, protein design, transmembrane proteins, innate immunity, inflammation, NF-κB signaling, Scripps Research, membrane biophysics, apolar packing, drug design, computational biology, PNAS